Trial Condition(s):
Venous Thromboembolism
Xarelto for VTE prophylaxis after hip or knee arthroplasty (XAMOS)
Bayer Identifier:
13802
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The main goal is to provide additional information to the risk-benefit assessment of the drug.
Inclusion Criteria
- Female and male patients who will undergo elective hip or knee arthroplasty.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United Kingdom | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, France | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Italy | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Sweden | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Portugal | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Hungary | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Greece | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Slovakia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, South Korea | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Hong Kong, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Singapore | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Latvia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Macedonia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Mexico | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Spain | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Belgium | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Netherlands | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Denmark | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Czech Republic | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Australia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Austria | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Lithuania | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Finland | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Venezuela | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Estonia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Serbia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Cyprus | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, South Africa | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Norway | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Chile | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Colombia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Brazil | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Bosnia and Herzegovina | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Lebanon | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Philippines | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Switzerland | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United Arab Emirates | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, India | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Vietnam | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Xarelto in the prophylaxis of post surgical venous thromboembolism after elective major orthopedic surgery of hip or knee
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Data collection on: Bleeding events reported as serious or non-serious adverse events; Symptomatic thromboembolic events (DVT, PE) reported as adverse events; Uncommon adverse events (incidence rate between 0.1 % and 1 %); All cause mortalityTimeframe: During observation period of three months
Additional Information
Copyright © Bayer
Powered by
